SG Americas Securities LLC Invests $251,000 in Replimune Group, Inc. (NASDAQ:REPL)

SG Americas Securities LLC purchased a new position in Replimune Group, Inc. (NASDAQ:REPL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,917 shares of the company’s stock, valued at approximately $251,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in shares of Replimune Group in the first quarter valued at $927,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group in the first quarter valued at $1,088,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares during the period. Millennium Management LLC lifted its holdings in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after buying an additional 53,313 shares during the period. Institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on REPL. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Monday, September 16th. Roth Mkm began coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Replimune Group presently has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Trading Down 1.6 %

Shares of NASDAQ REPL opened at $11.35 on Tuesday. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $15.18. The company has a market cap of $697.06 million, a price-to-earnings ratio of -3.50 and a beta of 1.21. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $10.81 and a 200-day simple moving average of $8.89.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.10. Sell-side analysts predict that Replimune Group, Inc. will post -3.11 EPS for the current year.

Insider Buying and Selling

In related news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.60% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.